GlucoTrack, Inc.(GCTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GCTK GlucoTrack, Inc.

Post-Mkt 05-01 17:21:42 EDT

0.8000

-0.0539

-6.31%

盘后0.7801

-0.0199-2.49%

17:21 EDT

High0.8458	Low0.7623	Vol1.25M
Open0.8410	D1 Closing0.8539	Amplitude9.78%
Mkt Cap1.56M	Tradable Cap681.84K	Total Shares1.94M
T/O1.01M	T/O Rate146.97%	Tradable Shares852.30K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GCTK","market":"US","secType":"STK","nameCN":"GlucoTrack, Inc.","latestPrice":0.8,"timestamp":1777665600000,"preClose":0.8539,"halted":0,"volume":1252588,"hourTrading":{"tag":"盘后","latestPrice":0.7801,"preClose":0.8,"latestTime":"17:21 EDT","volume":3560,"amount":2810.95464,"timestamp":1777670499641,"change":-0.0199,"changeRate":-0.024875,"amplitude":0.042},"delay":0,"changeRate":-0.06312214545028685,"floatShares":852300,"shares":1944300,"eps":-31.22,"marketStatus":"Post-Mkt","change":-0.0539,"latestTime":"05-01 17:21:42 EDT","open":0.841,"high":0.8458,"low":0.7623,"amount":1008963.3917639999,"amplitude":0.097787,"askPrice":0.81,"askSize":700,"bidPrice":0.7778,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-31.22,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777680000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8539,"preHourTrading":{"tag":"盘前","latestPrice":0.7858,"preClose":0.8539,"latestTime":"09:28 EDT","volume":56974,"amount":44320.93262844,"timestamp":1777642134229,"change":-0.0681,"changeRate":-0.079752,"amplitude":0.058672},"postHourTrading":{"tag":"盘后","latestPrice":0.7801,"preClose":0.8,"latestTime":"17:21 EDT","volume":3560,"amount":2810.95464,"timestamp":1777670499641,"change":-0.0199,"changeRate":-0.024875,"amplitude":0.042},"volumeRatio":0.060499},"requestUrl":"/m/hq/s/GCTK/tweets","defaultTab":"tweets","newsList":[{"id":"2631630137","title":"Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2631630137","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631630137?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:00","pubTimestamp":1777554000,"startTime":"0","endTime":"0","summary":"In-Vivo Ovine Study Demonstrates Sustained Performance Of Company’s Continuous Blood Glucose Monitoring (CBGM) Technology Over 240 Days, Reinforces Path to Key IDE SubmissionRUTHERFORD, N.J., April  3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284914/0/en/Glucotrack-Announces-Publication-of-Peer-Reviewed-Study-In-The-Journal-of-Diabetes-Research-Demonstrating-Long-Term-Accuracy-and-Stability-of-Continuous-Blood-Glucose-Monitoring-Te.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GCTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629032071","title":"GlucoTrack announces publication of peer-reviewed article on glucose sensors","url":"https://stock-news.laohu8.com/highlight/detail?id=2629032071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629032071?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:32","pubTimestamp":1776778343,"startTime":"0","endTime":"0","summary":"Glucotrack (GCTK) announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers, IEEE, S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/glucotrack-announces-publication-of-peer-reviewed-article-on-glucose-sensors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/glucotrack-announces-publication-of-peer-reviewed-article-on-glucose-sensors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","GCTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629036254","title":"Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2629036254","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629036254?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:00","pubTimestamp":1776772800,"startTime":"0","endTime":"0","summary":"Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review of the longevity and func","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3277876/0/en/Glucotrack-Announces-Publication-of-Peer-Reviewed-Study-Supporting-Long-Life-Sensor-Design-for-Implantable-Continuous-Blood-Glucose-Monitoring-Technology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627428216","title":"GlucoTrack issues 895,000 unregistered shares in $600,000 note exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2627428216","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627428216?lang=en_us&edition=fundamental","pubTime":"2026-04-15 00:16","pubTimestamp":1776183375,"startTime":"0","endTime":"0","summary":"GlucoTrack entered an exchange agreement dated April 13, 2026 to issue up to 895,000 unregistered common shares to an investor.Shares will be issued in exchange for a $600,000 partitioned promissory note carved out of a $3.6 million note.Issuance may be split into tranches due to a 19.9% beneficial ownership cap.Company relied on Securities Act Section 3 exemption for share issuance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL4hMV2K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GCTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623460321","title":"GlucoTrack Q4 EPS $(3.97) Up From $(1.24 thousand) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2623460321","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623460321?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:08","pubTimestamp":1774904930,"startTime":"0","endTime":"0","summary":"GlucoTrack (NASDAQ:GCTK) reported quarterly losses of $(3.97) per share. This is a 99.68 percent increase over losses of $(1.24 thousand) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51553960/glucotrack-q4-eps-3-97-up-from-1-24-thousand-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GlucoTrack Q4 EPS $(3.97) Up From $(1.24 thousand) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082",".IXIC","GCTK","NQmain","QLD","SQQQ","QDTE","FTEC","TQQQ","QID","JEPQ","NVIW.SI","PSQ","IYW","QYLG","QQQY","GPIQ","QQQJ","QQQE","MNQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623215783","title":"GlucoTrack FY25 net loss narrows to US$19.4 million; R&D expenses rise to US$9.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623215783","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623215783?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:50","pubTimestamp":1774903817,"startTime":"0","endTime":"0","summary":"GlucoTrack posted net loss of USD 19.4 million for full-year 2025, narrowing from USD 22.6 million.Operating loss widened to USD 16.1 million from USD 14.5 million.R&D expense rose to USD 9.8 million, while G&A expense increased to USD 6.3 million.Cash and cash equivalents climbed to USD 7.4 million, following a USD 4 million private placement in December 2025.Management said it plans to file an IDE in Q2 2026 and targets a U.S. clinical trial launch in second-half 2026, with cash expected to fund its 2026 operating plan through end of spring.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4vz7fx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","SG9999014021.USD","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","SG9999014005.SGD","BK4082","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623321658","title":"Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2623321658","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623321658?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:50","pubTimestamp":1774903800,"startTime":"0","endTime":"0","summary":"Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued paten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3265051/0/en/Glucotrack-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4082","PAB","PDN","IDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622822014","title":"Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622822014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622822014?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:29","pubTimestamp":1774618194,"startTime":"0","endTime":"0","summary":"Shares in diabetes-focused medical technology group Glucotrack ($GCTK) zoomed higher today after it said it was going to apply for a U.S. trial for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-glucotrack-stock-gctk-up-nearly-30-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-glucotrack-stock-gctk-up-nearly-30-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","GCTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821545","title":"GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821545","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821545?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:34","pubTimestamp":1774614869,"startTime":"0","endTime":"0","summary":"Glucotrack (GCTK) provided a recap of the critical operational milestones which have positioned the company to submit an IDE to the FDA for its con...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/glucotrack-to-file-ide-to-fda-for-continuous-blood-glucose-monitoring-technology-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/glucotrack-to-file-ide-to-fda-for-continuous-blood-glucose-monitoring-technology-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4082","GCTK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622829843","title":"BRIEF-Glucotrack To File Significant Ide With FDA For Us Clinical Trial In Early Q2 Based On Critical 2025 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2622829843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622829843?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:10","pubTimestamp":1774613441,"startTime":"0","endTime":"0","summary":"BRIEF-Glucotrack To File Significant Ide With FDA For Us Clinical Trial In Early Q2 Based On Critical 2025 MilestonesGlucoTrack Inc GCTK.O:GLUCOTRACK TO FILE SIGNIFICANT IDE WITH FDA FOR US CLINICAL T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nTUACDSTW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GCTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622287826","title":"GlucoTrack files FDA IDE in Q2 2026; first-in-human CBGM study posts 7.7% MARD","url":"https://stock-news.laohu8.com/highlight/detail?id=2622287826","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622287826?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:03","pubTimestamp":1774613039,"startTime":"0","endTime":"0","summary":"GlucoTrack said it plans to submit an investigational device exemption  to the FDA in Q2 2026 for a US clinical trial of its implantable continuous blood glucose monitoring technology.It reported results from a first-in-human, 5-day in-hospital study in Brazil with 10 participants, where the trial met primary and secondary endpoints.Reported performance metrics from the Brazil study included a mean absolute relative difference  of 7.7% and a 99% data capture rate.The company also said it initiated a feasibility clinical trial in Australia in July 2025 and used learnings from that study to update the protocol and product design.GlucoTrack expects the US study could begin in the second half of 2026, pending FDA approval of the IDE submission.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDLccpXyc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4585","IE00BGHQF748.EUR","BK4082","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014021.USD","SG9999014005.SGD","SG9999014039.USD","LU0314104364.USD","GCTK","BK4112","LU2210150020.SGD","LU2210149790.SGD","BK4588","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622682690","title":"GlucoTrack to File Significant Ide With FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2622682690","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622682690?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:01","pubTimestamp":1774612860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nTUACDSTW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619910110","title":"GlucoTrack Inc. Held Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2619910110","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619910110?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:06","pubTimestamp":1773432397,"startTime":"0","endTime":"0","summary":"GlucoTrack Inc. held a special meeting of stockholders on March 12, 2026. Stockholders approved the Nasdaq stock issuance proposal related to the Sixth Borough Capital Fund equity line of credit, approved the Nasdaq stock issuance proposal related to shares issuable upon exercise of common warrants from a private placement, and approved the auditor ratification of CBIZ CPAs P.C. for the year ended Dec. 31, 2025. The adjournment proposal was not presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL6FlbYJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607352110","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:42 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2607352110","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607352110?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:42","pubTimestamp":1769697750,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:42 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nAQN2LJSAA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607808746","title":"GlucoTrack Secures USPTO Patents for Fully Implantable Continuous Blood Glucose Monitoring System","url":"https://stock-news.laohu8.com/highlight/detail?id=2607808746","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607808746?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:02","pubTimestamp":1769691760,"startTime":"0","endTime":"0","summary":"GlucoTrack Inc. announced that the US Patent and Trademark Office has issued three patents for its continuous blood glucose monitoring  platform. The patents, US 12,453,494, US 12,458,257, and US 12,458,258, cover innovations including proprietary sensor chemistry, intravascular lead design, and low-power electronics for a fully implantable, long-term glucose sensor. The CBGM system is designed to provide up to three years of continuous, accurate blood glucose monitoring directly from blood, aiming to deliver real-time readings and improved convenience for users.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via GlobeNewswire  on January 29, 2026, and is s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL32m7HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014021.USD","GCTK","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4082","SG9999014013.SGD","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","BK4588","BK4585","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595797539","title":"Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2595797539","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595797539?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:00","pubTimestamp":1767099600,"startTime":"0","endTime":"0","summary":"Rutherford, NJ., Dec.  30, 2025  (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (the “Company”), a medical technology company focused on the design, development, and commercialization of novel te","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/30/3211348/0/en/Glucotrack-Inc-Announces-Pricing-of-4-0-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules-with-a-Single-Institutional-Investor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583051246","title":"GlucoTrack Q3 EPS $(4.64) Up From $(1.09 thousand) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583051246","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583051246?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:31","pubTimestamp":1763069477,"startTime":"0","endTime":"0","summary":"GlucoTrack (NASDAQ:GCTK) reported quarterly losses of $(4.64) per share. This is a 99.58 percent increase over losses of $(1.09 thousand) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851307/glucotrack-q3-eps-4-64-up-from-1-09-thousand-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USAW.SI","QLD","GCTK",".IXIC","SQQQ","USJW.SI","NQmain","PSQ","QID","TQQQ","TSYW.SI","MNQmain","BK4082","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583514177","title":"Glucotrack reports Q3 net loss of $15.8 million on $7.9 million cash balance","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514177","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583514177?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:13","pubTimestamp":1763068406,"startTime":"0","endTime":"0","summary":"Glucotrack Inc. reported a net loss of $15.8 million, or $30.1 per share, for the nine months ended September 30, 2025, compared to a net loss of $12.5 million, or $2,868 per share, for the same period in 2024. The increase in net loss was primarily due to higher general and administrative expenses and non-cash fair value changes in derivative liabilities. Marketing and general and administrative expenses were $4.4 million, up from $2.9 million a year earlier. Cash and cash equivalents as of September 30, 2025, were $7.9 million, compared to $5.6 million at December 31, 2024. During the period, Glucotrack secured $3 million in funding through a note purchase agreement and expanded its clinical advisory team. The company plans to submit an Investigational Device Exemption to the FDA for its continuous blood glucose monitor technology in spring 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL5vXp9n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581183234","title":"GlucoTrack Inc. Held Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581183234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581183234?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:16","pubTimestamp":1762553775,"startTime":"0","endTime":"0","summary":"GlucoTrack Inc. reconvened a special meeting of stockholders on November 7, 2025, after an initial adjournment on October 31, 2025. No proposals were approved, as the meeting was adjourned and cancelled due to lack of a quorum, and no business was conducted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL3qLJTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581986820","title":"GlucoTrack Adjourns Shareholder Meeting Due to Lack of Quorum","url":"https://stock-news.laohu8.com/highlight/detail?id=2581986820","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581986820?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:46","pubTimestamp":1762433165,"startTime":"0","endTime":"0","summary":"GlucoTrack Inc. disclosed that its special meeting of stockholders, originally convened on October 31, 2025, was adjourned due to a lack of quorum, with only 16.4% of outstanding shares represented. Stockholders approved the proposal to adjourn the meeting, with 136,928 votes in favor, 8,655 against, and 1,923 abstentions. The adjourned meeting is scheduled for November 7, 2025, at which stockholders will be asked to vote on the Issuance Proposal. Only shareholders of record as of September 23, 2025, are entitled to vote.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1Rt8w6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.integrity-app.com","stockEarnings":[{"period":"1week","weight":0.1707},{"period":"1month","weight":0.3137},{"period":"3month","weight":-0.5529},{"period":"6month","weight":-0.868},{"period":"1year","weight":-0.9178},{"period":"ytd","weight":-0.7794}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.1051},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.296},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.283543},{"month":2,"riseRate":0.375,"avgChangeRate":-0.064968},{"month":3,"riseRate":0.375,"avgChangeRate":-0.278807},{"month":4,"riseRate":0.625,"avgChangeRate":0.152362},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.073453},{"month":6,"riseRate":0.25,"avgChangeRate":-0.057411},{"month":7,"riseRate":0.375,"avgChangeRate":-0.041087},{"month":8,"riseRate":0.25,"avgChangeRate":0.001865},{"month":9,"riseRate":0.625,"avgChangeRate":0.152897},{"month":10,"riseRate":0.125,"avgChangeRate":-0.163128},{"month":11,"riseRate":0.375,"avgChangeRate":-0.123827},{"month":12,"riseRate":0.5,"avgChangeRate":0.25507}],"exchange":"NASDAQ","name":"GlucoTrack, Inc.","nameEN":"GlucoTrack, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GlucoTrack, Inc.(GCTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GlucoTrack, Inc.(GCTK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GlucoTrack, Inc.,GCTK,GlucoTrack, Inc.股票,GlucoTrack, Inc.股票老虎,GlucoTrack, Inc.股票老虎国际,GlucoTrack, Inc.行情,GlucoTrack, Inc.股票行情,GlucoTrack, Inc.股价,GlucoTrack, Inc.股市,GlucoTrack, Inc.股票价格,GlucoTrack, Inc.股票交易,GlucoTrack, Inc.股票购买,GlucoTrack, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GlucoTrack, Inc.(GCTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GlucoTrack, Inc.(GCTK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}